BioCryst Pharmaceuticals announces BCX4208 compound outcomes for treating gout BioCryst Pharmaceuticals, Inc. announced positive top-line outcomes from its randomized, double-blind, multi-center, placebo-controlled Stage 2 study made to evaluate the urate-decreasing activity and protection of several dosages of BCX4208 only and in conjunction with selected dosages of allopurinol administered once-daily. The principal endpoint was modify in serum the crystals concentration after 21 days of treatment in comparison to baseline concentration ahead of treatment.Melanie S. Nichols, of Deakin University in Geelong, Australia, warned that the battle is far from over. Nichols also revealed excess weight is still common amongst Australian children as young as 2 and low income kids remain at greater risk. In this scholarly study the team discovered that between 1999 and 2007, there is a gradual decline in the %age of obese and obese 2 – and 3-year-olds in the Australian state of Victoria. Just over 15 % of 3-and-a-half-year-olds were obese or obese in 2007, down from 18.5 % in 1999. Among 2-year-olds, the rate dipped from 13.5 % to just over 12 %. Among 3-and-a-half-year-olds, 4.5 % were obese in 1999, versus under 3 % in 2007 simply. This improvement was largely among lower income children, which meant that the interpersonal disparities in early-childhood weight problems rates have narrowed over time say researchers.